

Appl. No. 09/873,952
Amtd. Dated September 26, 2003
Reply to Final Office Action of March 26, 2003

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

BEST AVAILABLE COPY

Claims 1-8 (Canceled)

Claim 9 (previously presented): A composition containing an antineoplastic alkylphospholipid, and an antineoplastic antiestrogen in a lipid vesicle.

Claim 10 (previously presented): A liposome composition which comprises

- (i) an antineoplastic alkylphospholipid,
 - (ii) an antineoplastic water -or lipid-soluble antiestrogen associated in liposomal form with said antineoplastic alkylphospholipid,
 - (iii) a nonneoplastic phospholipid, and
- optionally one or more of (iv) a sterol, (v) a positively or negatively charged lipid, and (vi) a PEG lipid.

Claim 11 (currently amended): The composition of claim 10, wherein said alkylphospholipid has the formula



wherein

R is a C₁₂₋₂₂ alkyl, alkenyl, or ~~alkenyl~~ alkynyl residue,

Y is oxygen, sulfur, or a CH₂ residue,

P is a PO₂ residue, and

X is a choline, or modified choline residue, or serine, ethanolamine, or glycerine group, or a synthetic modification thereof.

Claim 12 (currently amended): The composition of claim 10, wherein said alkylphospholipid is ~~hexadecylphosphocholine~~ hexadecylphosphocholine.

Appl. No. 09/873,952
 Amtd. Dated September 26, 2003
 Reply to Final Office Action of March 26, 2003

octadecylphosphocholine, erucylphosphocholine, octadecyl-[2-(N-methylpiperidino)ethyl]phosphate, octadecylphosphoethanolamine, or hexadecylphosphoserine.

Claim 13 (currently amended): The composition of claim 10, wherein said antiestrogen is tamoxifen, droloxifen, toremifen, idoxiphen, raloxiphen, ~~miproxiphen-phosphate (TAT-59), ICI 164,3384, ICI 182,780, a main metabolite of tamoxiphen, 4-hydroxy-tamoxiphen, N-desmethyltamoxiphen~~ idoxifene, raloxifene, miproxifene-phosphate (TAT-59), 7 α -[9-[N-butyl-N-methylaminocarbonyl]decyl]estra-1,3,5(10)-triene-3,17 β -diol, 7 α -[9-[4,4,5,5,5-pentafluoropentyl]sulfonyl]nonyl]estra-1,3,5(10)-triene-3,17 β -diol, 4-hydroxytamoxifen, N-desmethyltamoxifen.

Claim 14 (previously presented): The composition of claim 10, wherein said nonneoplastic phospholipid is a naturally occurring or synthetic material, with a lipid : antiestrogen molar ratio of between 0-10 : 1 (m/m).

Claim 15 (previously presented): The composition of claim 14, wherein said nonneoplastic phospholipid is phosphocholine, serine, ethanolamine, glycerol.

Claim 16 (previously presented): The composition of claim 10, wherein said sterol is cholesterol, or sitosterol in a sterol : alkylphospholipid molar ratio of 0-1 : 1.

Claim 17 (currently amended): The composition of claim 10, wherein said PEG lipid is N-(O-methoxy-polyethyleneglycyl)-1,2-distearyl-s,n-glycero-3-phosphoethanolamine (PEG₂₀₀₀-DSPE) 1,2-Distearoyl-s,n-glycero-3-phosphoethanolamine-N-polyethyleneglycol.

Claim 18 (currently amended): The composition of claim 10, wherein said antineoplastic phospholipid is OPP octadecyl-(N,N-dimethylpiperidin-4-yl)-phosphate, and said antineoplastic antiestrogen is tamoxiphen tamoxifen.